VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 3 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $0 | – | 0 | – | 0.00% | – |
| Q1 2021 | $0 | – | 0 | – | 0.00% | – |
| Q4 2020 | $0 | – | 0 | – | 0.00% | – |
| Q3 2020 | $0 | – | 0 | – | 0.00% | – |
| Q2 2020 | $0 | – | 0 | – | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q2 2018 | $688,000 | +42.1% | 29,618 | +27.2% | 0.03% | +31.8% |
| Q1 2018 | $484,000 | 0.0% | 23,277 | 0.0% | 0.02% | 0.0% |
| Q4 2017 | $484,000 | -73.6% | 23,277 | -81.8% | 0.02% | -69.9% |
| Q3 2017 | $1,836,000 | -17.3% | 128,095 | -0.2% | 0.07% | -22.3% |
| Q2 2017 | $2,220,000 | +57.4% | 128,305 | +0.4% | 0.09% | +54.1% |
| Q1 2017 | $1,410,000 | -16.0% | 127,796 | +10.6% | 0.06% | -24.7% |
| Q4 2016 | $1,678,000 | -60.6% | 115,556 | -33.4% | 0.08% | -63.5% |
| Q3 2016 | $4,262,000 | +22.9% | 173,588 | +0.8% | 0.22% | +14.4% |
| Q2 2016 | $3,467,000 | -77.6% | 172,134 | +12.8% | 0.19% | -81.4% |
| Q4 2015 | $15,509,000 | – | 152,572 | – | 1.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |